Loss of the malignant phenotype of human neuroblastoma cells by a catalytically inactive dominant-negative hTERT mutant

Molecular Cancer Therapeutics

Volumn 11, Issue 11, 2012, Pages 2384-2393

  Samy, Mona ^a,b,c   Gattolliat, Charles Henry ^d   Pendino, Frédéric ^a,b   Hillion, Josette ^a,b   Nguyen, Eric ^a,b   Bombard, Sophie ^a,b   Douc Rasy, Sétha ^d   Bénard, Jean ^d   Ségal Bendirdjian, Evelyne ^a,b  

^a INSERM   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

^d INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CISPLATIN; DOMINANT NEGATIVE HUMAN TELOMERASE REVERSE TRANSCRIPTASE MUTANT; MUTANT PROTEIN; MYCN PROTEIN; PROTEIN; PROTEIN P53; RETROVIRUS VECTOR; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL STRUCTURE; CELL VIABILITY; CLONOGENESIS; COPY NUMBER VARIATION; DNA FINGERPRINTING; ENZYME ACTIVITY; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VIVO STUDY; MALIGNANT PHENOTYPE; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; ONCOGENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TELOMERE SHORTENING; TUMOR XENOGRAFT;

ANIMALS; APOPTOSIS; BIOCATALYSIS; CASPASE 8; CELL LINE, TUMOR; CELL SHAPE; CELL TRANSFORMATION, NEOPLASTIC; CHILD; GENES, DOMINANT; GENOME, HUMAN; HUMANS; MALE; MICE; MICE, NUDE; MUTANT PROTEINS; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PHENOTYPE; TELOMERASE; TELOMERE HOMEOSTASIS; TRANSDUCTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84869236566     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0281     Document Type: Article

References (43)

1. Brodeur GM. Neuroblastoma: biological insights into a clinical enigma. Nat Rev Cancer 2003;3:203-16. (Pubitemid 37328872)
2. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224:1121-4. (Pubitemid 14106392)
3. Ambros IM, Rumpler S, Luegmayr A, Hattinger CM, Strehl S, Kovar H, et al. Neuroblastoma cells can actively eliminate supernumerary MYCN gene copies by micronucleus formation - sign of tumour cell revertance? Eur J Cancer 1997;33:2043-9. (Pubitemid 28123451)
4. Prochazka P, Hrabeta J, Vicha A, Eckschlager T. Expulsion of amplified MYCN from homogenously staining chromosomal regions in neuroblastoma cell lines after cultivation with cisplatin, doxorubicin, hydroxyurea, and vincristine. Cancer Genet Cytogenet 2010;196:96-104.
5. Krelin Y, Zhang L, Kang TB, Appel E, Kovalenko A, Wallach D. Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ 2008;15:1350-5.
6. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, Valentine VA, et al. Caspase 8 is deleted or silenced preferentially in childhood neuroblastomas with amplification of MYCN. Nat Med 2000;6:529-35. (Pubitemid 30305902)
7. Eggert A, Grotzer MA, Zuzak TJ, Wiewrodt BR, Ho R, Ikegaki N, et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res 2001;61:1314-9. (Pubitemid 34292549)
8. Hopkins-Donaldson S, Bodmer JL, Bourloud KB, Brognara CB, Tschopp J, Gross N. Loss of caspase-8 expression in neuroblastoma is related to malignancy and resistance to TRAIL-induced apoptosis. Med Pediatr Oncol 2000;35:608-11.
9. Moll UM, LaQuaglia M, Benard J, Riou G. Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc Natl Acad Sci U S A 1995;92:4407-11.
10. Ross RA, Spengler BA, Biedler JL. Coordinate morphological and biochemical interconversion of human neuroblastoma cells. J Natl Cancer Inst 1983;71:741-7. (Pubitemid 14232388)
11. Ciccarone V, Spengler BA, Meyers MB, Biedler JL, Ross RA. Phenotypic diversification in human neuroblastoma cells: expression of distinct neural crest lineages. Cancer Res 1989;49:219-25. (Pubitemid 19024435)
12. Blackburn EH. Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Lett 2005;579:859-62. (Pubitemid 40361854)
13. Gorbunova V, Seluanov A, Pereira-Smith OM. Expression of human telomerase (hTERT) does not prevent stress-induced senescence in normal human fibroblasts but protects the cells from stress-induced apoptosis and necrosis. J Biol Chem 2002;277:38540-9. (Pubitemid 35154713)
14. Dudognon C, Pendino F, Hillion J, Saumet A, Lanotte M, Segal-Bendirdjian E. Death receptor signaling regulatory function for telomerase: hTERT abolishes TRAIL-induced apoptosis, independently of telomere maintenance. Oncogene 2004;23:7469-74. (Pubitemid 39389688)
15. Lee J, Sung YH, Cheong C, Choi YS, Jeon HK, Sun W, et al. TERT promotes cellular and organismal survival independently of telomerase activity. Oncogene 2008;27:3754-60. (Pubitemid 351912970)
16. Choi J, Southworth LK, Sarin KY, Venteicher AS, Ma W, Chang W, et al. TERT promotes epithelial proliferation through transcriptional control of a Myc- and Wnt-related developmental program. PLoS Genet 2008;4:e10.
17. Masutomi K, Possemato R, Wong JM, Currier JL, Tothova Z, Manola JB, et al. The telomerase reverse transcriptase regulates chromatin state and DNA damage responses. Proc Natl Acad Sci U S A 2005;102:8222-7. (Pubitemid 40800070)
18. Smith LL, Coller HA, Roberts JM. Telomerase modulates expression of growth-controlling genes and enhances cell proliferation. Nat Cell Biol 2003;5:474-9. (Pubitemid 36592272)
19. Pendino F, Tarkanyi I, Dudognon C, Hillion J, Lanotte M, Aradi J, et al. Telomeres and telomerase: pharmacological targets for new anticancer strategies? Curr Cancer Drug Targets 2006;6:147-80.
20. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med 1999;5:1164-70. (Pubitemid 29474421)
21. Nguyen BN, Elmore LW, Holt SE. Mechanism of dominant-negative telomerase function. Cell Cycle 2009;8:3227-33.
22. Poynter KR, Sachs PC, Bright AT, Breed MS, Nguyen BN, Elmore LW, et al. Genetic inhibition of telomerase results in sensitization and recovery of breast tumor cells. Mol Cancer Ther 2009;8:1319-27.
23. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med 1995;1:249-55.
24. Reynolds CP, Zuo JJ, Kim NW, Wang H, Lukens JN, Matthay KK, et al. Telomerase expression in primary neuroblastomas. Eur J Cancer 1997;33:1929-31. (Pubitemid 28123427)
25. Ferrandis E, Da Silva J, Riou G, Bénard J. Coactivation of MDR1 and MYCN genes in human neuroblastoma cells during the metastatic process in thye nude mouse. Cancer Res 1994;54:2256-61. (Pubitemid 24138705)
26. Valent A, Venuat AM, Danglot G, Da Silva J, Duarte N, Bernheim A, et al. Stromal cells and human malignant neuroblasts derived from bone marrow metastasis may share common karyotypic abnormalities: the case of the IGR-N-91 cell line. Med Pediatr Oncol 2001;36:100-3.
27. Goldschneider D, Horvilleur E, Plassa LF, Guillaud-Bataille M, Million K, Wittmer-Dupret E, et al. Expression of C-terminal deleted p53 isoforms in neuroblastoma. Nucleic Acids Res 2006;34:5603-12. (Pubitemid 44742447)
28. Raguenez G, Muhlethaler-Mottet A, Meier R, Duros C, Benard J, Gross N. Fenretinide-induced caspase-8 activation and apoptosis in an established model of metastatic neuroblastoma. BMC Cancer 2009;9:97.
29. Pendino F, Flexor M, Delhommeau F, Buet D, Lanotte M, Segal-Bendirdjian E. Retinoids down-regulate telomerase and telomere length in a pathway distinct from leukemia cell differentiation. Proc Natl Acad Sci U S A 2001;98:6662-7. (Pubitemid 32538273)
30. Deville L, Hillion J, Pendino F, Samy M, Nguyen E, Segal-Bendirdjian E. hTERT promotes imatinib resistance in chronic myeloid leukemia cells: therapeutic implications. Mol Cancer Ther 2011;10:711-9.
31. Segal-Bendirdjian E, Jacquemin-Sablon A. Cisplatin resistance in a murine leukemia cell line is associated with a defective apoptotic process. Exp Cell Res 1995;218:201-12.
32. Wu YL, Dudognon C, Nguyen E, Hillion J, Pendino F, Tarkanyi I, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci 2006;119:2797-806. (Pubitemid 44184016)
33. Misawa M, Tauchi T, Sashida G, Nakajima A, Abe K, Ohyashiki JH, et al. Inhibition of human telomerase enhances the effect of chemotherapeutic agents in lung cancer cells. Int J Oncol 2002;21:1087-92.
34. Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T, et al. Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy. Hum Gene Ther 2005;16:859-68. (Pubitemid 40982334)
35. Ward RJ, Autexier C. Pharmacological telomerase inhibition can sensitize drug-resistant and drug-sensitive cells to chemotherapeutic treatment. Mol Pharmacol 2005;68:779-86. (Pubitemid 41206032)
36. Cerone MA, Londono-Vallejo A, Autexier C. Telomerase inhibition enhances the response to anticancer drug treatment in human breast cancer cells. Mol Cancer Ther 2006;5:1669-75. (Pubitemid 44323234)
37. Li S, Crothers J, Haqq CM, Blackburn EH. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 2005;280:23709-17. (Pubitemid 40884853)
38. Delhommeau F, Thierry A, Feneux D, Lauret E, Leclercq E, Courtier MH, et al. Telomere dysfunction and telomerase reactivation in human leukemia cell lines after telomerase inhibition by the expression of a dominant-negative hTERT mutant. Oncogene 2002;21:8262-71. (Pubitemid 35477866)
39. Brassat U, Balabanov S, Bali D, Dierlamm J, Braig M, Hartmann U, et al. Functional p53 is required for effective execution of telomerase inhibition in BCR-ABL-positive CML cells. Exp Hematol 2011;39:66-76 e1-2.
40. Bichara M, Wagner J, Lambert IB. Mechanisms of tandem repeat instability in bacteria. Mutat Res 2006;598:144-63. (Pubitemid 43870101)
41. Usuda J, Inomata M, Fukumoto H, Iwamoto Y, Suzuki T, Kuh HJ, et al. Restoration of p53 gene function in 12-O-tetradecanoylphorbor 13-acetate-resistant human leukemia K562/TPA cells. Int J Oncol 2003;22:81-6.
42. Stupack DG, Teitz T, Potter MD, Mikolon D, Houghton PJ, Kidd VJ, et al. Potentiation of neuroblastoma metastasis by loss of caspase-8. Nature 2006;439:95-9. (Pubitemid 43053635)
43. Teitz T, Lahti JM, Kidd VJ. Aggressive childhood neuroblastomas do not express caspase-8: an important component of programmed cell death. J Mol Med 2001;79:428-36. (Pubitemid 32757468)